Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Int J Mol Sci ; 24(1)2023 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-36614177

RESUMEN

FROUNT is an intracellular protein that promotes pseudopodia formation by binding to the chemokine receptors CCR2 and CCR5 on macrophages. Recently, disulfiram (DSF), a drug treatment for alcoholism, was found to have FROUNT inhibitory activity. In this study, we investigated the effect of DSF eye drops in a rat corneal alkali burn model. After alkali burn, 0.5% DSF eye drops (DSF group) and vehicle eye drops (Vehicle group) were administered twice daily. Immunohistochemical observations and real-time reverse transcription-polymerase chain reaction (RT-PCR) analyses were performed at 6 h and 1, 4, and 7 days after alkali burn. Results showed a significant decrease in macrophage accumulation in the cornea in the DSF group, but no difference in neutrophils. RT-PCR showed decreased expression of macrophage-associated cytokines in the DSF group. Corneal scarring and neovascularization were also suppressed in the DSF group. Low-vacuum scanning electron microscopy imaging showed that macrophage length was significantly shorter in the DSF group, reflecting the reduced extension of pseudopodia. These results suggest that DSF inhibited macrophage infiltration by suppressing macrophage pseudopodia formation.


Asunto(s)
Quemaduras Químicas , Lesiones de la Cornea , Neovascularización de la Córnea , Quemaduras Oculares , Ratas , Animales , Disulfiram/farmacología , Disulfiram/uso terapéutico , Quemaduras Químicas/tratamiento farmacológico , Quemaduras Químicas/metabolismo , Soluciones Oftálmicas/farmacología , Álcalis/farmacología , Seudópodos/metabolismo , Córnea/metabolismo , Macrófagos/metabolismo , Lesiones de la Cornea/tratamiento farmacológico , Lesiones de la Cornea/metabolismo , Neovascularización de la Córnea/tratamiento farmacológico , Quemaduras Oculares/inducido químicamente , Quemaduras Oculares/tratamiento farmacológico , Quemaduras Oculares/metabolismo , Modelos Animales de Enfermedad
2.
Int J Mol Sci ; 23(17)2022 Aug 29.
Artículo en Inglés | MEDLINE | ID: mdl-36077171

RESUMEN

Many studies have demonstrated the therapeutic effects of hydrogen in pathological conditions such as inflammation; however, little is known about its prophylactic effects. The purpose of this study is to investigate the prophylactic effects of hydrogen-rich water instillation in a rat corneal alkali burn model. Hydrogen-rich water (hydrogen group) or physiological saline (vehicle group) was instilled continuously to the normal rat cornea for 5 min. At 6 h after instillation, the cornea was exposed to alkali. The area of corneal epithelial defect (CED) was measured every 6 h until 24 h after alkali exposure. In addition, at 6 and 24 h after injury, histological and immunohistochemical observations were made and real-time reverse transcription polymerase chain reaction (RT-PCR) was performed to investigate superoxide dismutase enzyme (SOD)1, SOD2, and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) mRNA expression. CED at 12 h and the number of inflammatory infiltrating cells at 6 h after injury were significantly smaller in the hydrogen group than the vehicle group. Furthermore, SOD1 expression was significantly higher in the hydrogen group than the vehicle group at both 6 and 24 h, and the number of PGC-1α-positive cells was significantly larger in the hydrogen group than the vehicle group at 6 h after injury. In this model, prophylactic instillation of hydrogen-rich water suppressed alkali burn-induced inflammation, likely by upregulating expression of antioxidants such as SOD1 and PGC-1α. Hydrogen has not only therapeutic potential but also prophylactic effects that may suppress corneal scarring following injury and promote wound healing.


Asunto(s)
Quemaduras Químicas , Lesiones de la Cornea , Quemaduras Oculares , Queratitis , Álcalis/farmacología , Animales , Antioxidantes/uso terapéutico , Quemaduras Químicas/tratamiento farmacológico , Quemaduras Químicas/metabolismo , Lesiones de la Cornea/tratamiento farmacológico , Modelos Animales de Enfermedad , Quemaduras Oculares/tratamiento farmacológico , Hidrógeno/farmacología , Hidrógeno/uso terapéutico , Inflamación , Ratas , Superóxido Dismutasa/genética , Superóxido Dismutasa/farmacología , Superóxido Dismutasa-1/uso terapéutico , Agua/farmacología , Cicatrización de Heridas
3.
Pharmaceuticals (Basel) ; 14(2)2021 Jan 25.
Artículo en Inglés | MEDLINE | ID: mdl-33504094

RESUMEN

The effects of each subtype-selective peroxisome proliferator activated receptor (PPAR) agonist (α, ß/δ, γ) on corneal epithelial wound healing were investigated using a rat corneal alkali burn model. After the alkali burn, each PPAR agonist or vehicle ophthalmic solution was instilled topically onto the rat's cornea. Corneal epithelial healing processes were evaluated by fluorescein staining. Pathological analyses and real-time reverse transcription polymerase chain reactions were performed to evaluate Ki67 (proliferative maker) expression and inflammatory findings. The area of the corneal epithelial defect at 12 h and 24 h after the alkali burn was significantly smaller in each PPAR group than in the vehicle group. Ki67 mRNA expression was increased in the PPARß/δ group, whereas mRNA expressions of inflammatory cytokines were suppressed in all of the PPAR agonist groups. Nuclear factor kappa B (NF-κB) was the most suppressed in the PPARγ group. The accelerated corneal epithelial healing effects of each PPAR ligand were thought to be related to the promotion of proliferative capacity and inhibition of inflammation.

4.
Transl Vis Sci Technol ; 9(6): 14, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32821511

RESUMEN

Purpose: Wound healing processes in a rat corneal alkali burn model were observed using low-vacuum scanning electron microscopy (LV-SEM), a new observation method that can use paraffin sections for light microscopic immunostaining. Methods: Injured cornea was observed under immunohistochemistry, LV-SEM, and transmission electron microscopy. In LV-SEM, periodic acid-methenamine silver staining was used to observe collagen and platinum blue staining was used to observe vascular endothelial cells. Analyses of the messenger RNA expression involved in neovascularization processes after wound creation were also performed. Results: LV-SEM depicted progression of corneal wound healing in a stereoscopic fashion. In neovascularization processes after wound creation, LV-SEM with osmification clearly demonstrated detachment of pericytes from the vascular endothelial cells, in association with up-regulation of angiopoietin-2 messenger RNA expression. Conclusions: LV-SEM enables high magnification observation of paraffin sections used for immunohistochemistry. LV-SEM provides easy, detailed observations and offers a promising new observational modality in the field of ophthalmology. Translational Relevance: High magnification analysis was easily available using LV-SEM with conventional paraffin sections for light microscopy.


Asunto(s)
Córnea , Células Endoteliales , Animales , Microscopía Electrónica de Rastreo , Ratas , Vacio , Cicatrización de Heridas
5.
Int J Ophthalmol ; 13(8): 1173-1179, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32821669

RESUMEN

AIM: To investigate the effects of hydrogen (H2) on Cu, Zn superoxide dismutase (SOD1) activation in a rat model of corneal alkali burn. METHODS: In each rat, one cornea was subjected to alkali exposure. Physiological saline (saline group) or H2-dissolved saline (H2 group) was instilled continuously on the cornea for 5min before and after alkali exposure. Inflammatory cells, neovascularization, and cytoplasmic SOD1 levels were evaluated immunohistochemically in enucleated eyes from both groups. Three-dimensional ultrastructural tissue changes in the eyes were analyzed using low-vacuum scanning electron microscopy. RESULTS: The numbers of both inflammatory and vascular endothelial cells were significantly reduced in the corneas of the H2 group (P<0.01). Furthermore, H2 treatment increased both cytoplasmic SOD1 levels (P<0.01) and activity in corneal epithelial cells (P<0.01). Notably, the SOD1 activity level in the H2 group was approximately 2.5-fold greater than that in the saline group. CONCLUSION: H2 treatment suppresses inflammation and neovascularization in the injured cornea and indirectly suppresses oxidative insult to the cornea by upregulating the SOD1 enzyme protein level and activity.

6.
Int J Mol Sci ; 21(14)2020 Jul 19.
Artículo en Inglés | MEDLINE | ID: mdl-32707656

RESUMEN

Peroxisome proliferator-activated receptor alpha (PPARα) and gamma (PPARγ) agonists have anti-inflammatory and anti-neovascularization effects, but few reports have tested the combination of PPARα and PPARγ agonists. In this study, we investigated the therapeutic effects of ophthalmic solutions of agonists of PPARα, PPARγ, and the combination in a rat corneal alkali burn model. After alkali injury, an ophthalmic solution of 0.05% fenofibrate (PPARα group), 0.1% pioglitazone (PPARγ group), 0.05% fenofibrate + 0.1% pioglitazone (PPARα+γ group), or vehicle (vehicle group) was topically instilled onto the rat's cornea twice a day. After instillation, upregulation was seen of PPAR mRNA corresponding to each agonist group. Administration of agonists for PPARα, PPARγ, and PPARα+γ suppressed inflammatory cells, neovascularization, and fibrotic changes. In addition, the PPARγ agonist upregulated M2 macrophages, which contributed to wound healing, whereas the PPARα agonist suppressed immature blood vessels in the early phase. Administration of PPARα+γ agonists showed therapeutic effects in corneal wound healing, combining the characteristics of both PPARα and PPARγ agonists. The results indicate that the combination of PPARα and γ agonists may be a new therapeutic strategy.


Asunto(s)
Quemaduras Químicas/tratamiento farmacológico , Lesiones de la Cornea/tratamiento farmacológico , Quemaduras Oculares/tratamiento farmacológico , PPAR alfa/agonistas , PPAR gamma/agonistas , Animales , Quemaduras Químicas/metabolismo , Quemaduras Químicas/patología , Lesiones de la Cornea/metabolismo , Lesiones de la Cornea/patología , Neovascularización de la Córnea/prevención & control , Citocinas/genética , Modelos Animales de Enfermedad , Quimioterapia Combinada , Quemaduras Oculares/metabolismo , Quemaduras Oculares/patología , Fenofibrato/administración & dosificación , Fibrosis , Queratitis/prevención & control , Masculino , Soluciones Oftálmicas , PPAR alfa/genética , PPAR alfa/metabolismo , PPAR gamma/genética , PPAR gamma/metabolismo , Pioglitazona/administración & dosificación , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Ratas Wistar
7.
Int J Mol Sci ; 21(15)2020 Jul 26.
Artículo en Inglés | MEDLINE | ID: mdl-32722564

RESUMEN

The effects of peroxisome proliferator-activated receptor (PPAR)ß/δ ophthalmic solution were investigated in a rat corneal alkali burn model. After alkali injury, GW501516 (PPARß/δ agonist) or vehicle ophthalmic solution was topically instilled onto the rat's cornea twice a day until day 7. Pathological findings were evaluated, and real-time reverse transcription polymerase chain reaction was performed. GW501516 strongly suppressed infiltration of neutrophils and pan-macrophages, and reduced the mRNA expression of interleukin-6, interleukin-1ß, tumor necrosis factor alpha, and nuclear factor-kappa B. On the other hand, GW501516 promoted infiltration of M2 macrophages, infiltration of vascular endothelial cells associated with neovascularization in the wounded area, and expression of vascular endothelial growth factor A mRNA. However, 7-day administration of GW501516 did not promote neovascularization in uninjured normal corneas. Thus, the PPARß/δ ligand suppressed inflammation and promoted neovascularization in the corneal wound healing process. These results will help to elucidate the role of PPARß/δ in the field of ophthalmology.


Asunto(s)
Lesiones de la Cornea/patología , Neovascularización Fisiológica/efectos de los fármacos , PPAR delta/agonistas , PPAR-beta/agonistas , Tiazoles/farmacología , Animales , Lesiones de la Cornea/tratamiento farmacológico , Lesiones de la Cornea/metabolismo , Modelos Animales de Enfermedad , Regulación de la Expresión Génica/efectos de los fármacos , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Inflamación/patología , Interleucina-1beta/biosíntesis , Interleucina-6/biosíntesis , Masculino , Ratas , Ratas Wistar , Factor A de Crecimiento Endotelial Vascular/biosíntesis
8.
Molecules ; 24(1)2018 Dec 29.
Artículo en Inglés | MEDLINE | ID: mdl-30597991

RESUMEN

We investigated the effect of a peroxisome proliferator-activated receptor α (PPARα) agonist after corneal alkali injury. Fenofibrate 0.05% (PPARα agonist group) or vehicle (Vehicle group) was topically instilled onto the rat cornea after injury. Histological, immunohistochemical, and real-time reverse transcription PCR analyses were performed. PPARα-positive cells were observed among basal cells of the corneal epithelium in normal and alkali-burned corneas. The number of infiltrating neutrophils and macrophages at the corneal limbus was lower in the PPARα agonist group. Interleukin-1ß (IL-1ß), IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), and vascular endothelial growth factor-An mRNA expression was suppressed in the PPARα agonist group compared to the Vehicle group. mRNA levels of nuclear factor kappa B (NF-κB) in corneal tissue were not different. However, NF-κB was expressed in the cytoplasm of basal cells in the PPARα agonist group and in the nucleus in the Vehicle group. MCP-1 was more weakly expressed in the PPARα agonist group. The PPARα agonist inhibited inflammation during the early phase after injury. Anti-inflammatory effects of the PPARα agonist included prevention of up-regulation of proinflammatory cytokines and MCP-1, and prevention of inflammatory cell infiltration into the injured cornea. Thus, a PPARα agonist may be a promising treatment for corneal injury.


Asunto(s)
Quimiocina CCL2/metabolismo , Citocinas/metabolismo , Mediadores de Inflamación/metabolismo , Queratitis/etiología , Queratitis/metabolismo , FN-kappa B/metabolismo , PPAR alfa/agonistas , Álcalis/efectos adversos , Animales , Biomarcadores , Modelos Animales de Enfermedad , Inmunohistoquímica , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Macrófagos/metabolismo , Macrófagos/patología , PPAR alfa/metabolismo , Transporte de Proteínas , Ratas
9.
Sci Rep ; 7(1): 17763, 2017 12 19.
Artículo en Inglés | MEDLINE | ID: mdl-29259285

RESUMEN

We investigated the effect of a peroxisome proliferator-activated receptor alpha (PPARα) agonist ophthalmic solution in wound healing using a rat corneal alkali burn model. After instillation of a selective agonist of PPARα, fenofibrate, onto the burned cornea, PPARα-positive cells were observed in vascular endothelial cells, and there was upregulation of mRNA of PPARα in corneal stroma. Fenofibrate suppressed expression of neutrophils and macrophages during the early phase, and development of neovascularization and myofibroblast generation during the late phase. Fenofibrate reduced not only mRNA expression of vascular endothelial growth factor-A but also angiopoietin-1 and angiopoietin-2. Furthermore, fenofibrate suppressed scar formation by reducing type III collagen expression. These data suggest that a PPARα agonist ophthalmic solution might be a new strategy for treating corneal wounds through not only anti-inflammatory effects but also by preventing neovascularization.


Asunto(s)
Álcalis/farmacología , Angiopoyetina 2/metabolismo , Lesiones de la Cornea/tratamiento farmacológico , Neovascularización de la Córnea/tratamiento farmacológico , Quemaduras Oculares/tratamiento farmacológico , PPAR alfa/agonistas , Factores de Crecimiento Endotelial Vascular/metabolismo , Angiopoyetina 1/metabolismo , Animales , Quemaduras Químicas/tratamiento farmacológico , Quemaduras Químicas/metabolismo , Cicatriz/tratamiento farmacológico , Cicatriz/metabolismo , Colágeno Tipo III/metabolismo , Córnea/efectos de los fármacos , Córnea/metabolismo , Lesiones de la Cornea/metabolismo , Neovascularización de la Córnea/metabolismo , Modelos Animales de Enfermedad , Células Endoteliales/metabolismo , Quemaduras Oculares/metabolismo , Fenofibrato/farmacología , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Masculino , Miofibroblastos/efectos de los fármacos , Miofibroblastos/metabolismo , Neovascularización Patológica/tratamiento farmacológico , Neovascularización Patológica/metabolismo , Neutrófilos/efectos de los fármacos , Neutrófilos/metabolismo , Soluciones Oftálmicas/farmacología , ARN Mensajero/metabolismo , Ratas , Regulación hacia Arriba/efectos de los fármacos , Cicatrización de Heridas/efectos de los fármacos
10.
Mol Vis ; 19: 2135-50, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24194635

RESUMEN

PURPOSE: We clarified the effects of an ophthalmic solution of a peroxisome proliferator-activated receptor gamma (PPARγ) agonist on corneal inflammation and wound healing after alkali burn injury in rats. METHODS: After alkali exposure, either an ophthalmic solution with 0.1% pioglitazone hydrochloride (the PPARγ group) or vehicle (the vehicle group) was topically applied to the cornea until day 14. Histological, immunohistochemical, and real-time reverse transcription polymerase chain reaction analysis were performed. RESULTS: After alkali injury, PPARγ expression increased, with the infiltration of many inflammatory cells. The infiltration of neutrophils and macrophages started from the corneal limbus within 6 h, and developed in the corneal center by day 7, with associated neovascularization. The accumulation of α-smooth muscle actin-positive myofibroblasts and the deposition of type III collagen were noted on day 14. The histological changes were suppressed significantly by treatment with the ophthalmic solution of the PPARγ agonist. In addition, the number of infiltrating M2 macrophages in the cornea was increased by PPARγ agonist treatment. In real-time reverse transcription polymerase chain reaction analysis, the messenger ribonucleic acid expression levels of interleukin-1ß (IL-1ß), IL-6, IL-8, monocyte chemoattractant protein-1, tumor necrosis factor-α, transforming growth factor beta 1, and vascular endothelial growth factor-A were decreased in the PPARγ group compared to the vehicle group in the early periods of corneal inflammation. CONCLUSIONS: The ophthalmic solution of the PPARγ agonist inhibited inflammation, decreased the fibrotic reaction, and prevented neovascularization in the cornea from the early phase after alkali burn injury. The ophthalmic solution of the PPARγ agonist may provide a new treatment strategy with useful clinical applications for corneal inflammation and wound healing.


Asunto(s)
Quemaduras Químicas/tratamiento farmacológico , Córnea/patología , Quemaduras Oculares/tratamiento farmacológico , Inflamación/prevención & control , Soluciones Oftálmicas/farmacología , Soluciones Oftálmicas/uso terapéutico , PPAR gamma/agonistas , Álcalis , Animales , Quemaduras Químicas/complicaciones , Quemaduras Químicas/patología , Quimiocinas/genética , Quimiocinas/metabolismo , Colágeno Tipo III/metabolismo , Córnea/efectos de los fármacos , Neovascularización de la Córnea/tratamiento farmacológico , Neovascularización de la Córnea/patología , Opacidad de la Córnea/complicaciones , Opacidad de la Córnea/tratamiento farmacológico , Opacidad de la Córnea/patología , Modelos Animales de Enfermedad , Quemaduras Oculares/complicaciones , Quemaduras Oculares/patología , Fibrosis , Inflamación/complicaciones , Inflamación/tratamiento farmacológico , Macrófagos/efectos de los fármacos , Macrófagos/patología , Masculino , Infiltración Neutrófila/efectos de los fármacos , PPAR gamma/metabolismo , Pioglitazona , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Tiazolidinedionas/farmacología , Tiazolidinedionas/uso terapéutico , Cicatrización de Heridas/efectos de los fármacos
11.
Lab Invest ; 92(8): 1149-60, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22614125

RESUMEN

Renal fibrosis is a common finding in progressive renal diseases. Matrix metalloproteinases (MMPs) are involved in epithelial-to-mesenchymal transition (EMT). We investigated the role of MMP-2 and the effect of inhibition of MMPs on the development of renal fibrosis. Renal fibrosis was induced in MMP-2 wild-type (MMP-2⁺/⁺) mice by unilateral ureteral obstruction (UUO). Renal histopathology, EMT-associated molecules, and activity of MMP-2 and MMP-9 were examined during the development of interstitial fibrosis. UUO-renal fibrosis was also induced in MMP-2 deficient (MMP-2⁻/⁻) and MMP-2⁺/⁺ mice treated with minocycline (inhibitor of MMPs). In MMP-2⁺/⁺ mice, MMP-2 and MMP-9 were expressed in damaged tubules, and their activities increased in a time-dependent manner after UUO. Interstitial fibrosis was noted at day 14, with deposition of types III and I collagens and expression of markers of mesenchymal cells (S100A4, vimentin, α-smooth muscle actin, and heat shock protein-47) in damaged tubular epithelial cells, together with F4/80+ macrophage infiltration. Fibrotic kidneys expressed EMT-associated molecules (ILK, TGF-ß1, Smad, Wnt, ß-catenin, and Snail). In contrast, the kidneys of MMP-2⁻/⁻ mice and minocycline-treated MMP-2⁺/⁺ mice showed amelioration of renal fibrosis with reduced expression of markers of mesenchymal cells in tubular epithelial cells, inhibition of upregulated EMT-associated molecules, and suppression of macrophage infiltration. The results suggested that MMP-2 have a pathogenic role in renal interstitial fibrosis, possibly through the induction of EMT and macrophage infiltration. Inhibition of MMPs may be beneficial therapeutically in renal fibrosis.


Asunto(s)
Transición Epitelial-Mesenquimal , Enfermedades Renales/metabolismo , Metaloproteinasa 2 de la Matriz/metabolismo , Obstrucción Ureteral/metabolismo , Animales , Colágeno/metabolismo , Células Epiteliales , Fibrosis/enzimología , Fibrosis/genética , Fibrosis/metabolismo , Fibrosis/patología , Regulación de la Expresión Génica , Histocitoquímica , Enfermedades Renales/genética , Enfermedades Renales/patología , Túbulos Renales/química , Túbulos Renales/patología , Masculino , Metaloproteinasa 2 de la Matriz/genética , Metaloproteinasa 9 de la Matriz/genética , Metaloproteinasa 9 de la Matriz/metabolismo , Inhibidores de la Metaloproteinasa de la Matriz , Ratones , Ratones Transgénicos , Minociclina , Fenotipo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Proteína de Unión al Calcio S100A4 , Proteínas S100 , Obstrucción Ureteral/genética , Obstrucción Ureteral/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA